Xentuzumab BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody|cas:1417158-65-6|西域试剂

Xentuzumab BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

产品编号：Bellancom-P99274| CAS NO：1417158-65-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99274		￥4200.00	杭州北京（现货）
Bellancom-P99274		￥10900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Xentuzumab BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody

产品介绍

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) 是重组的人源化单克隆抗体，靶向 IGF 配体 IGF1 和 IGF2。Xentuzumab 抑制 IGF1 和 IGF2 的生长促进信号，抑制 AKT 的激活。

生物活性

Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF1 and IGF2. Xentuzumab inhibits both of IGF1 and IGF2 growth-promoting signalling and suppresses AKT activation.

体外研究

Xentuzumab (0.01-1 mM; 96 h) inhibits IGF type 1 receptor signaling and (0.1 μM; 48 h) AKT serine/threonine kinase (AKT) phosphorylation in VCaP, DuCaP, and MDA PCa 2b cell in a dose-dependent manner.
Xentuzumab (0.01-1 mM; 5-10 d) losses of antiproliferative activity against PTEN-null LNCaP or PC-3 cells when PTEN knockdown.
Xentuzumab (1 μM; 24-72 h) arrests cell cycle at sub-G1 phase and induces apoptosis in VCaP cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis

Cell Line:	Prostate cancer VCaP cells
Concentration:	0.1 μM
Incubation Time:	24 h and 48 h
Result:	Increased in cleaved caspase 3/7 and PARP. Decreased the level of phosphorylation of FoxO3a (S253)/FoxO1 (T24).

Cell Cycle Analysis

Cell Line:	Prostate cancer VCaP cells
Concentration:	1 μM
Incubation Time:	24 h, 48 h, and 72 h
Result:	Increased in cleaved caspase 3/7 and induces cell apoptosis. Increased the sub-G1 cell population.

体内研究
(In Vivo)

Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
Result:	Resulted in significant reductions in tumor volume.

体内研究

Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
Result:	Resulted in significant reductions in tumor volume.

体内研究

Xentuzumab (200 mg/kg i.p., once weekly for 10 weeks) in inhibits tumor growth in LuCaP 96CR patient-derived xenograft model in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Fox Chase CB17 severe combined immunodeficiency (SCID; CB17/lcr-Prkdc scid/lcrlcoCrl) male mice with LuCaP 96CR cell (s.c.)
Dosage:	200 mg/kg
Administration:	Intraperitoneal injection; once weekly for 10 weeks; sacrificed 6 hours after the last dose
Result:	Resulted in significant reductions in tumor volume.